Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL

详细信息    查看全文

• 作者：Alena Vaculova (1)
  Vitaliy Kaminskyy (1)
  Elham Jalalvand (1)
  Olga Surova (1)
  Boris Zhivotovsky (1)
  
• 刊名：Molecular Cancer
• 出版年：2010
• 出版时间：December 2010
• 年：2010
• 卷：9
• 期：1
• 全文大小：1868KB
• 参考文献：1. Zhivotovsky B, Orrenius S: Defects in the apoptotic machinery of cancer cells: role in drug resistance. / Semin Cancer Biol 2003, 13:125鈥?34. CrossRef
  2. Rodriguez-Nieto S, Zhivotovsky B: Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment. / Curr Pharm Des 2006, 12:4411鈥?425. CrossRef
  3. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, / et al.: Identification and characterization of a new member of the TNF family that induces apoptosis. / Immunity 1995, 3:673鈥?82. CrossRef
  4. Newsom-Davis T, Prieske S, Walczak H: Is TRAIL the holy grail of cancer therapy? / Apoptosis 2009, 14:607鈥?23. CrossRef
  5. Koschny R, Walczak H, Ganten TM: The promise of TRAIL--potential and risks of a novel anticancer therapy. / J Mol Med 2007, 85:923鈥?35. CrossRef
  6. MacFarlane M: TRAIL-induced signalling and apoptosis. / Toxicol Lett 2003, 139:89鈥?7. CrossRef
  7. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, / et al.: Safety and antitumor activity of recombinant soluble Apo2 ligand. / J Clin Invest 1999, 104:155鈥?62. CrossRef
  8. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, / et al.: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. / Nat Med 1999, 5:157鈥?63. CrossRef
  9. Shivapurkar N, Reddy J, Matta H, Sathyanarayana UG, Huang CX, Toyooka S, Minna JD, Chaudhary PM, Gazdar AF: Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. / Oncogene 2002, 21:8510鈥?514. CrossRef
  10. Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C, Zangemeister-Wittke U, Stahel R: Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. / Cell Death Differ 2003, 10:356鈥?64. CrossRef
  11. Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF: Apoptosis and lung cancer: a review. / J Cell Biochem 2003, 88:885鈥?98. CrossRef
  12. Joseph B, Ekedahl J, Sirzen F, Lewensohn R, Zhivotovsky B: Differences in expression of pro-caspases in small cell and non-small cell lung carcinoma. / Biochem Biophys Res Commun 1999, 262:381鈥?87. CrossRef
  13. Adams JM, Cory S: Bcl-2-regulated apoptosis: mechanism and therapeutic potential. / Curr Opin Immunol 2007, 19:488鈥?96. CrossRef
  14. Robertson JD, Enoksson M, Suomela M, Zhivotovsky B, Orrenius S: Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. / J Biol Chem 2002, 277:29803鈥?9809. CrossRef
  15. Wu XX, Ogawa O, Kakehi Y: TRAIL and chemotherapeutic drugs in cancer therapy. / Vitam Horm 2004, 67:365鈥?83. CrossRef
  16. Debatin KM, Krammer PH: Death receptors in chemotherapy and cancer. / Oncogene 2004, 23:2950鈥?966. CrossRef
  17. Bergh J, Nilsson K, Ekman R, Giovanella B: Establishment and characterization of cell lines from human small cell and large cell carcinomas of the lung. / Acta Pathol Microbiol Immunol Scand A 1985, 93:133鈥?47.
  18. Walczak H, Haas TL: Biochemical analysis of the native TRAIL death-inducing signaling complex. / Methods Mol Biol 2008, 414:221鈥?39. CrossRef
  19. Vaculova A, Zhivotovsky B: Caspases: determination of their activities in apoptotic cells. / Methods Enzymol 2008, 442:157鈥?81. CrossRef
  20. Galligan L, Longley DB, McEwan M, Wilson TR, McLaughlin K, Johnston PG: Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. / Mol Cancer Ther 2005, 4:2026鈥?036. CrossRef
  21. Belyanskaya LL, Ziogas A, Hopkins-Donaldson S, Kurtz S, Simon HU, Stahel R, Zangemeister-Wittke U: TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. / Lung Cancer 2008, 60:355鈥?65. CrossRef
  22. Shivapurkar N, Toyooka S, Eby MT, Huang CX, Sathyanarayana UG, Cunningham HT, Reddy JL, Brambilla E, Takahashi T, Minna JD, / et al.: Differential inactivation of caspase-8 in lung cancers. / Cancer Biol Ther 2002, 1:65鈥?9. CrossRef
  23. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM: Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. / Oncogene 2001, 20:5865鈥?877. CrossRef
  24. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT: Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. / Cancer Res 2001, 61:1645鈥?651.
  25. Liu W, Bodle E, Chen JY, Gao M, Rosen GD, Broaddus VC: Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. / Am J Respir Cell Mol Biol 2001, 25:111鈥?18.
  26. Wu XX, Jin XH, Zeng Y, El Hamed AM, Kakehi Y: Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression. / Cancer Sci 2007, 98:1969鈥?976. CrossRef
  27. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ: Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. / Cancer Res 2000, 60:847鈥?53.
  28. MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH, Cohen GM: Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. / Oncogene 2002, 21:6809鈥?818. CrossRef
  29. Liu X, Yue P, Khuri FR, Sun SY: Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. / Cancer Res 2005, 65:9169鈥?175. CrossRef
  30. Dumitru CA, Carpinteiro A, Trarbach T, Hengge UR, Gulbins E: Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms. / Apoptosis 2007, 12:1533鈥?541. CrossRef
  31. Krueger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S: Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. / J Biol Chem 2001, 276:20633鈥?0640. CrossRef
  32. Geserick P, Drewniok C, Hupe M, Haas TL, Diessenbacher P, Sprick MR, Schon MP, Henkler F, Gollnick H, Walczak H, Leverkus M: Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. / Oncogene 2008, 27:3211鈥?220. CrossRef
  33. Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH, Walczak H: Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. / Cancer Res 2000, 60:553鈥?59.
  34. Kelly MM, Hoel BD, Voelkel-Johnson C: Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. / Cancer Biol Ther 2002, 1:520鈥?27. CrossRef
  35. White SJ, Lu P, Keller GM, Voelkel-Johnson C: Targeting the short form of cFLIP by RNA interference is sufficient to enhance TRAIL sensitivity in PC3 prostate carcinoma cells. / Cancer Biol Ther 2006, 5:1618鈥?623. CrossRef
  36. Guseva NV, Rokhlin OW, Taghiyev AF, Cohen MB: Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L). / Breast Cancer Res Treat 2008, 107:349鈥?57. CrossRef
  37. Xiao C, Yang BF, Song JH, Schulman H, Li L, Hao C: Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis. / Exp Cell Res 2005, 304:244鈥?55. CrossRef
  38. Kreuz S, Siegmund D, Scheurich P, Wajant H: NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. / Mol Cell Biol 2001, 21:3964鈥?973. CrossRef
  39. Wajant H, Haas E, Schwenzer R, Muhlenbeck F, Kreuz S, Schubert G, Grell M, Smith C, Scheurich P: Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD). / J Biol Chem 2000, 275:24357鈥?4366. CrossRef
  40. Wilson TR, Redmond KM, McLaughlin KM, Crawford N, Gately K, O'Byrne K, Le-Clorrenec C, Holohan C, Fennell DA, Johnston PG, Longley DB: Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing. / Cell Death Differ 2009,16(10):1352鈥?1. CrossRef
  41. Panaretakis T, Pokrovskaja K, Shoshan MC, Grander D: Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. / J Biol Chem 2002, 277:44317鈥?4326. CrossRef
  42. Nguyen DM, Yeow WS, Ziauddin MF, Baras A, Tsai W, Reddy RM, Chua A, Cole GW Jr, Schrump DS: The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell death. / Cancer J 2006, 12:257鈥?73. CrossRef
  43. Shamimi-Noori S, Yeow WS, Ziauddin MF, Xin H, Tran TL, Xie J, Loehfelm A, Patel P, Yang J, Schrump DS, / et al.: Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway. / Cancer Gene Ther 2008, 15:356鈥?70. CrossRef
  44. Panaretakis T, Laane E, Pokrovskaja K, Bjorklund AC, Moustakas A, Zhivotovsky B, Heyman M, Shoshan MC, Grander D: Doxorubicin requires the sequential activation of caspase-2, protein kinase Cdelta, and c-Jun NH2-terminal kinase to induce apoptosis. / Mol Biol Cell 2005, 16:3821鈥?831. CrossRef
  45. Lassus P, Opitz-Araya X, Lazebnik Y: Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. / Science 2002, 297:1352鈥?354. CrossRef
  46. Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R, Dorken B, Daniel PT: Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. / Blood 2001, 97:1378鈥?387. CrossRef
  47. Engels IH, Stepczynska A, Stroh C, Lauber K, Berg C, Schwenzer R, Wajant H, Janicke RU, Porter AG, Belka C, / et al.: Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. / Oncogene 2000, 19:4563鈥?573. CrossRef
  48. Inoue S, Browne G, Melino G, Cohen GM: Ordering of caspases in cells undergoing apoptosis by the intrinsic pathway. / Cell Death Differ 2009, 16:1053鈥?061. CrossRef
  
• 作者单位：Alena Vaculova (1)
  Vitaliy Kaminskyy (1)
  Elham Jalalvand (1)
  Olga Surova (1)
  Boris Zhivotovsky (1)
  
  1. Institute of Environmental Medicine, Division of Toxicology, Karolinska Institutet, Box 210, SE, 171 77, Stockholm, Sweden
  
• ISSN：1476-4598

文摘

Background TRAIL is considered as a promising anti-cancer agent, because of its ability to induce apoptosis in cancer but not in most normal cells. However, growing evidence exist that many cancer cells are resistant to its apoptotic effects. SCLC is a typical example of tumor entity where TRAIL monotherapy is not efficient. Results We demonstrated that doxorubicin and etoposide markedly sensitized SCLC cells expressing caspase-8 to apoptotic effects of TRAIL. The drug-mediated sensitization of these cells was associated with increase of surface and total DR5 protein level, specific cleavage of cFLIPL, decrease of cFLIPS level, and a strong activation of caspase-8. The involvement of mitochondria-mediated pathway was demonstrated by enhanced Bid cleavage, Bax activation, and cytochrome c release. Activation of caspase-8 induced by combined treatment was shown to occur upstream of mitochondria and effector caspases. Conclusions Our results highlight significant applicability of doxorubicin and etoposide in sensitization of SCLC cells expressing caspase-8 to treatment with TRAIL.